BAJAJ BROKING
Sun Pharma posted consolidated revenue of Rs.1.29 lakh crore and net profit of Rs.21,499 crore in Q4 FY25. For FY25, total income reached Rs.5.45 lakh crore and PAT stood at Rs.1.09 lakh crore, reflecting strong growth in core operations.
Sun Pharma delivered a robust financial performance in Q4 FY25, led by consistent growth in both domestic and international markets. The company’s consolidated revenue rose 8% year-on-year to Rs.1,29,588 crore, while net profit increased 18.6% to Rs.21,499 crore. For the full year, Sun Pharma reported Rs.5,25,784 crore in revenue and Rs.1,09,290 crore in net profit. Margin expansion and increased R&D investments highlighted the company’s strategic focus on innovation and specialty drugs.
Q4 FY25 Revenue: Rs.1,29,588 crore, up 8% YoY
Q4 FY25 PAT: Rs.21,499 crore, up 18.6% YoY
FY25 Revenue: Rs.5,25,784 crore, up 8.4% YoY
FY25 PAT: Rs.1,09,290 crore, up 14% YoY
FY25 EBITDA (Est.): Rs.1,44,300 crore (approx. EBITDA margin ~27.4%)
EPS (FY25): Rs.45.6 vs Rs.39.9 in FY24
Dividend: Final dividend of Rs.5.50 per share declared (Total FY25: Rs.16.00 per share)
Particulars | Q4 FY25 (Rs. Cr) | Q4 FY24 (Rs. Cr) | YoY Change |
Total Income | 1,35,717 | 1,25,888 | +7.8% |
EBITDA (Est.) | 36,160 | 29,171 | +23.9% |
EBITDA Margin (%) | ~28.5% | ~23.2% | +530 bps |
Profit Before Tax | 32,544 | 28,155 | +15.6% |
Profit After Tax | 21,499 | 18,573* | +15.8% |
PAT Margin (%) | 15.8% | 14.8% | +100 bps |
EPS (Rs.) | 9.0 | 7.7* | +16.9% |
*Estimate based on FY24 quarterly PAT average |
Sun Pharma operates in a single reportable segment — Pharmaceuticals — with strong performance across geographies.
India Business: Maintains leadership in branded generics
US Market: Growth driven by specialty and generics
Emerging Markets: Continued traction in Asia and LATAM
R&D Spend: Rs.7,904 crore in FY25, reflecting innovation push
Market expectations were optimistic, anticipating consistent growth in branded generics and margin improvement. Sun Pharma outperformed on profitability, aided by reduced forex losses and controlled expenses. The company’s performance was broadly above street estimates, especially on earnings and margin fronts.
The Board has proposed a final dividend of Rs.5.50 per share, raising the total FY25 payout to Rs.16.00. Sun Pharma also announced board-level changes, including the appointment of Ms. Vidhi Shanghvi as Whole-time Director and the retirement of Mr. Sudhir Valia.
Stay updated on Q4 FY25 earnings via our Quarterly Results Calendar featuring real-time schedules, forecasts, and financial summaries.
Source: The results above are derived from Sun Pharmaceutical Industries Ltd’s official BSE filings and financial disclosures as of May 22, 2025.
Share this article:
Disclaimer :
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading